TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025

Rhea-AI Summary

TransMedics (Nasdaq:TMDX) will report third quarter 2025 financial results after market close on Wednesday, October 29, 2025.

The TransMedics management team will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT; domestic dial-in is (844) 676-6010 and international dial-in is (412) 634-6944. A live and archived webcast will be available in the Investors section at https://investors.transmedics.com/.

News Market Reaction – TMDX

+2.73%

4 alerts

+2.73% Session close to close

$4.04B Market Cap

0.6x Rel. Volume

In the Oct 16 session, TMDX gained 2.73%, reflecting a moderate positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ANDOVER, Mass., Oct. 15, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

Investors interested in listening to the conference call may do so by dialing (844) 676-6010 for domestic callers or (412) 634-6944 for international callers and ask to be joined into the TransMedics call. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.   

About TransMedics Group, Inc.

TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
Investors@transmedics.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-third-quarter-2025-financial-results-on-october-29-2025-302585122.html

SOURCE TransMedics Group, Inc.

FAQ

When will TransMedics (TMDX) release third quarter 2025 results?

TransMedics will release third quarter 2025 results after market close on October 29, 2025.

What time is the TransMedics (TMDX) Q3 2025 earnings call?

The management call begins at 4:30 p.m. ET / 1:30 p.m. PT on the release date.

How can I join the TransMedics (TMDX) conference call on October 29, 2025?

Dial (844) 676-6010 (domestic) or (412) 634-6944 (international) and ask to be joined into the TransMedics call.

Where will the TransMedics (TMDX) webcast be available?

A live and archived webcast will be available in the Investors section at https://investors.transmedics.com/.

Will the TransMedics (TMDX) Q3 2025 webcast be archived for later viewing?

Yes. The company will provide an archived webcast in the Investors section of its website.

Are there separate dial-in numbers for domestic and international callers for the TransMedics call?

Yes. Domestic callers use (844) 676-6010; international callers use (412) 634-6944.